262 related articles for article (PubMed ID: 25581376)
1. Inhibitors of CLK protein kinases suppress cell growth and induce apoptosis by modulating pre-mRNA splicing.
Araki S; Dairiki R; Nakayama Y; Murai A; Miyashita R; Iwatani M; Nomura T; Nakanishi O
PLoS One; 2015; 10(1):e0116929. PubMed ID: 25581376
[TBL] [Abstract][Full Text] [Related]
2. Synergistic apoptotic effects in cancer cells by the combination of CLK and Bcl-2 family inhibitors.
Murai A; Ebara S; Sasaki S; Ohashi T; Miyazaki T; Nomura T; Araki S
PLoS One; 2020; 15(10):e0240718. PubMed ID: 33064779
[TBL] [Abstract][Full Text] [Related]
3. Anti-tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC-dependent vulnerability.
Iwai K; Yaguchi M; Nishimura K; Yamamoto Y; Tamura T; Nakata D; Dairiki R; Kawakita Y; Mizojiri R; Ito Y; Asano M; Maezaki H; Nakayama Y; Kaishima M; Hayashi K; Teratani M; Miyakawa S; Iwatani M; Miyamoto M; Klein MG; Lane W; Snell G; Tjhen R; He X; Pulukuri S; Nomura T
EMBO Mol Med; 2018 Jun; 10(6):. PubMed ID: 29769258
[TBL] [Abstract][Full Text] [Related]
4. Combination of Clk family kinase and SRp75 modulates alternative splicing of Adenovirus E1A.
Yomoda J; Muraki M; Kataoka N; Hosoya T; Suzuki M; Hagiwara M; Kimura H
Genes Cells; 2008 Mar; 13(3):233-44. PubMed ID: 18298798
[TBL] [Abstract][Full Text] [Related]
5. Akt2 regulation of Cdc2-like kinases (Clk/Sty), serine/arginine-rich (SR) protein phosphorylation, and insulin-induced alternative splicing of PKCbetaII messenger ribonucleic acid.
Jiang K; Patel NA; Watson JE; Apostolatos H; Kleiman E; Hanson O; Hagiwara M; Cooper DR
Endocrinology; 2009 May; 150(5):2087-97. PubMed ID: 19116344
[TBL] [Abstract][Full Text] [Related]
6. CLK-dependent exon recognition and conjoined gene formation revealed with a novel small molecule inhibitor.
Funnell T; Tasaki S; Oloumi A; Araki S; Kong E; Yap D; Nakayama Y; Hughes CS; Cheng SG; Tozaki H; Iwatani M; Sasaki S; Ohashi T; Miyazaki T; Morishita N; Morishita D; Ogasawara-Shimizu M; Ohori M; Nakao S; Karashima M; Sano M; Murai A; Nomura T; Uchiyama N; Kawamoto T; Hara R; Nakanishi O; Shumansky K; Rosner J; Wan A; McKinney S; Morin GB; Nakanishi A; Shah S; Toyoshiba H; Aparicio S
Nat Commun; 2017 Feb; 8(1):7. PubMed ID: 28232751
[TBL] [Abstract][Full Text] [Related]
7. The CLK inhibitor SM08502 induces anti-tumor activity and reduces Wnt pathway gene expression in gastrointestinal cancer models.
Tam BY; Chiu K; Chung H; Bossard C; Nguyen JD; Creger E; Eastman BW; Mak CC; Ibanez M; Ghias A; Cahiwat J; Do L; Cho S; Nguyen J; Deshmukh V; Stewart J; Chen CW; Barroga C; Dellamary L; Kc SK; Phalen TJ; Hood J; Cha S; Yazici Y
Cancer Lett; 2020 Mar; 473():186-197. PubMed ID: 31560935
[TBL] [Abstract][Full Text] [Related]
8. Conserved proline-directed phosphorylation regulates SR protein conformation and splicing function.
Keshwani MM; Aubol BE; Fattet L; Ma CT; Qiu J; Jennings PA; Fu XD; Adams JA
Biochem J; 2015 Mar; 466(2):311-22. PubMed ID: 25529026
[TBL] [Abstract][Full Text] [Related]
9. Cdc2-like kinases and DNA topoisomerase I regulate alternative splicing of tissue factor in human endothelial cells.
Eisenreich A; Bogdanov VY; Zakrzewicz A; Pries A; Antoniak S; Poller W; Schultheiss HP; Rauch U
Circ Res; 2009 Mar; 104(5):589-99. PubMed ID: 19168442
[TBL] [Abstract][Full Text] [Related]
10. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing.
Debdab M; Carreaux F; Renault S; Soundararajan M; Fedorov O; Filippakopoulos P; Lozach O; Babault L; Tahtouh T; Baratte B; Ogawa Y; Hagiwara M; Eisenreich A; Rauch U; Knapp S; Meijer L; Bazureau JP
J Med Chem; 2011 Jun; 54(12):4172-86. PubMed ID: 21615147
[TBL] [Abstract][Full Text] [Related]
11. A critical update on the strategies towards small molecule inhibitors targeting Serine/arginine-rich (SR) proteins and Serine/arginine-rich proteins related kinases in alternative splicing.
Tang J; Xie Y; Huang J; Zhang L; Jiang W; Li Z; Bian J
Bioorg Med Chem; 2022 Sep; 70():116921. PubMed ID: 35863237
[TBL] [Abstract][Full Text] [Related]
12. Connecting the speckles: Splicing kinases and their role in tumorigenesis and treatment response.
Corkery DP; Holly AC; Lahsaee S; Dellaire G
Nucleus; 2015; 6(4):279-88. PubMed ID: 26098145
[TBL] [Abstract][Full Text] [Related]
13. Human CDC2-like kinase 1 (CLK1): a novel target for Alzheimer's disease.
Jain P; Karthikeyan C; Moorthy NS; Waiker DK; Jain AK; Trivedi P
Curr Drug Targets; 2014 May; 15(5):539-50. PubMed ID: 24568585
[TBL] [Abstract][Full Text] [Related]
14. Kinase domain insertions define distinct roles of CLK kinases in SR protein phosphorylation.
Bullock AN; Das S; Debreczeni JE; Rellos P; Fedorov O; Niesen FH; Guo K; Papagrigoriou E; Amos AL; Cho S; Turk BE; Ghosh G; Knapp S
Structure; 2009 Mar; 17(3):352-62. PubMed ID: 19278650
[TBL] [Abstract][Full Text] [Related]
15. Novel CLK1 inhibitors based on N-aryloxazol-2-amine skeleton - A possible way to dual VEGFR2 TK/CLK ligands.
Murár M; Dobiaš J; Šramel P; Addová G; Hanquet G; Boháč A
Eur J Med Chem; 2017 Jan; 126():754-761. PubMed ID: 27940419
[TBL] [Abstract][Full Text] [Related]
16. Specific CLK inhibitors from a novel chemotype for regulation of alternative splicing.
Fedorov O; Huber K; Eisenreich A; Filippakopoulos P; King O; Bullock AN; Szklarczyk D; Jensen LJ; Fabbro D; Trappe J; Rauch U; Bracher F; Knapp S
Chem Biol; 2011 Jan; 18(1):67-76. PubMed ID: 21276940
[TBL] [Abstract][Full Text] [Related]
17. Structural Basis for the Selective Inhibition of Cdc2-Like Kinases by CX-4945.
Lee JY; Yun JS; Kim WK; Chun HS; Jin H; Cho S; Chang JH
Biomed Res Int; 2019; 2019():6125068. PubMed ID: 31531359
[TBL] [Abstract][Full Text] [Related]
18. The Clk/Sty protein kinase phosphorylates SR splicing factors and regulates their intranuclear distribution.
Colwill K; Pawson T; Andrews B; Prasad J; Manley JL; Bell JC; Duncan PI
EMBO J; 1996 Jan; 15(2):265-75. PubMed ID: 8617202
[TBL] [Abstract][Full Text] [Related]
19. SRPK1 and Clk/Sty protein kinases show distinct substrate specificities for serine/arginine-rich splicing factors.
Colwill K; Feng LL; Yeakley JM; Gish GD; Cáceres JF; Pawson T; Fu XD
J Biol Chem; 1996 Oct; 271(40):24569-75. PubMed ID: 8798720
[TBL] [Abstract][Full Text] [Related]
20. Mobilization of a splicing factor through a nuclear kinase-kinase complex.
Aubol BE; Keshwani MM; Fattet L; Adams JA
Biochem J; 2018 Feb; 475(3):677-690. PubMed ID: 29335301
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
